Eli Lilly’s drug tirzepatide, sold under the names Mounjaro for diabetes and Zepbound for weight loss, improved symptoms in heart failure patients with obesity, the company said Thursday.

Tirzepatide demonstrated statistically significant improvements in both primary endpoints with a reduction in the risk of heart failure outcomes, assessed as a composite endpoint, and improvements ...

Both primary endpoints were met. Tirzepatide showed a 38% reduction in the risk of heart failure outcomes, assessed as a composite endpoint, compared to placebo. Risk of hospitalization for heart ...

Tirzepatide reduced cardiovascular death or heart failure worsening by 38% in patients ... ejection fraction (HFpEF), it sharply cuts the risk of dying from a cardiovascular (CV) event or seeing ...

Data from the SUMMIT clinical trial demonstrated that tirzepatide lowered the risk of negative heart failure outcomes and enhanced symptoms and physical limitations when tested with three different ...

Sold as Zepbound and Mounjaro, the medication reduced the likelihood of hospitalization and death by nearly 40 percent in a new study. Tirzepatide lowered the risk of heart failure–related ...

The study found participants in the tirzepatide group had a reduced combined risk of cardiovascular death and worsening heart failure events compared to the participants in the placebo group.

Treatment with tirzepatide reduced the risk of time-to-first occurrence of heart failure outcomes by 38% compared with placebo. Treatment with tirzepatide was associated with a reduction in the ...